World Muscle Society Congress

A new analysis of a trial of ataluren in Duchenne and Becker muscular dystrophies due to nonsense mutations shows a low dose may slow decline in walking ability

posted on October 15, 2010 - 12:11pm
A low-dose regimen of ataluren (formerly called PTC124), an experimental drug developed by PTC Therapeutics to treat  Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) caused by a certain type of genetic mutation, is superior to a high-dose regimen or a placebo.

New content is being added every day. Please check back again.